January 29, 2019

Company name:	SanBio Co., Ltd.
Representative:	Keita Mori, Representative Director and President (TSE Mothers Code: 4592)
Contact:	Yoshihiro Kakutani, Corporate Officer of Management Administration (TEL: +81-3-6264-3481)

Topline Analytic Results of a Phase 2b Clinical Trial in the US of SB623 Regenerative Cell Medicine for Chronic Motor Deficit from Ischemic Stroke

Confirmed analytic results have indicated that it was not possible to meet the primary endpoint in a Phase 2b clinical trial of SB623 regenerative cell medicine for chronic motor deficit from ischemic stroke, which the SanBio Group is progressing in the US together with Sumitomo Dainippon Pharma Co., Ltd. (Note 1) Accordingly, the Company will review its method of moving forward with the Group's business.

The SB623 chronic motor deficit from traumatic brain injury (TBI) program obtained positive results in a Phase 2 trial (STEMTRA trial) (Note 2), so the Company aims to continue development and obtain domestic approval as soon as possible. With respect to other diseases, the Company will conduct a review of methods, timing, and necessary funds for development.

The Company expects to announce revised development and business plans for the fiscal year ending January 2020 onward by the results briefing for the fiscal year ending January 31, 2019 (scheduled for late March 2019) at the latest.

(Notes) 1. Please refer to the release entitled "SanBio Announces Topline Results from a Phase 2b Study in the U.S. Evaluating SB623, a Regenerative Cell Medicine for the Treatment of Patients with Chronic Stroke," dated today.

2. Please refer to the November 1, 2018 release entitled "SanBio Announces Phase 2 STEMTRA Trial Using SB623 Cells for Treatment of Patients with Traumatic Brain Injury Met Primary Endpoint."